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Abstract
Background: BSEP disease results from mutations in ABCB11, which encodes the bile salt export pump (BSEP).
BSEP disease is associated with an increased risk of hepatobiliary cancer.
Case Presentation: A 36 year old woman with BSEP disease developed pancreatic adenocarcinoma at age 36. She
had been treated with a biliary diversion at age 18. A 1.7 × 1.3 cm mass was detected in the pancreas on
abdominal CT scan. A 2 cm mass lesion was found at the neck and proximal body of the pancreas. Pathology
demonstrated a grade 2-3 adenocarcinoma with invasion into the peripancreatic fat.
Conclusions: Clinicians should be aware of the possibility of pancreatic adenocarcinoma in patients with BSEP
disease.
Background
Type 2 Progressive Familial Intrahepatic Cholestasis
(PFIC-2), also known as BSEP disease, is one of the
genetically determined cholestatic diseases and results
from mutations in ABCB11, which encodes the bile salt
export pump (BSEP) protein responsible for the bulk of
conjugated bile salt transport from hepatocytes into bili-
ary canaliculi. BSEP disease has an estimated incidence
in Western Europe of approximately 1 in 50,000-70,000
births [1]. While in most ways the clinical features of
PFIC-2 are similar to PFIC-1 (FIC1 disease due to muta-
tions in ATP8B1), it is uniquely associated with substan-
tially increased risk of hepatobiliary cancer. Early
presentation of hepatocellular carcinoma (HCC) was
reported in 10 children with BSEP disease [2], and cho-
langiocarcinoma, a very rare cancer in children, was
reported in 2 cases [3]. In a large survey of families with
severe BSEP disease, 15% of patients developed HCC or
cholangiocarcinoma [1]. This suggests that BSEP disease
carries a HCC risk somewhat equivalent to that of tyro-
sinemia type 1, among the highest for any genetic dis-
ease [4], and also a risk for cancer involving other
hepatic cell types, not seen in tyrosinemia. We describe
a woman with BSEP disease who developed Pancreatic
Adenocarcinoma and propose that this should be added
to the cancer risk imposed by BSEP disease. This is the
first reported case of pancreatic adenocarcinoma in a
person with BSEP disease.
Case Presentation
This female patient with BSEP disease presented at age
36 years for evaluation of a pancreatic mass. The muta-
tion in her ABCB11 gene involves heterozygote missense
mutations, one allelic mutation being 1238T>G
(Leu413Trp) and the other 3724C>A (Gly1242Ile), as
reported elsewhere [1]. She was diagnosed at age 18
with low-GGT PFIC when she presented with unremit-
ting cholestasis with severe pruritus. Her older male sib-
ling died prior to her birth at age 4 from cholestatic
liver disease and HCC. Her family history also included
pancreatic cancer in an uncle, colon cancer in two
uncles, and liver cancer in the maternal grandfather. She
underwent partial external biliary diversion for treat-
ment of cholestasis, as reported elsewhere [5]. Her
serum bile salts at diagnosis were >300 μmol/ml
(<10 μmol/ml) and normalized following biliary diver-
sion. She required treatment with ursodeoxycholic acid
(10 mg/kg/d) to maintain full relief from pruritus. With
this treatment, she was able to complete college and to
work as an accountant. She did not use tobacco. At ages
26 and 29, she had successful pregnancies resulting in
healthy unaffected children. However, with each of these
pregnancies she experienced prolonged, severe
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cholestasis with jaundice and itching. The second of the
two episodes was so severe that it prompted an exten-
sive evaluation for possible contributing factors. Endo-
scopic retrograde cholangiography demonstrated
patency of the external biliary diversion, and liver biopsy
demonstrated canalicular cholestasis, focal loss of bile
ducts and focal bridging fibrosis.
While being screened twice yearly for hepatocellular
carcinoma, a low-density enhancing mass lesion of the
pancreas was identified on abdominal CT scan measur-
ing 1.7 × 1.3 cm with dilatation of the pancreatic
duct within the body and tail upstream from the lesion
(Figure 1). No other focal mass lesions were identified
in the head, body or tail of the pancreas. Endoscopic
ultrasound-guided biopsy demonstrated clusters of
epithelial cells with atypia and mucin production. The
CEA level was 6.1 ng/ml (0-3 ng/ml) and CA 19-9 level
was 14.9 U/ml (<33 U/ml). At surgery a 2 cm mass
lesion was found at the neck and proximal body of the
pancreas with no gross extension into the portal vein or
hepatic artery. An extended distal pancreatectomy with
resection of the neck and proximal body of the pancreas
was performed. Sections from the pancreatic mass
demonstrated an infiltrative tumor composed of angu-
lated glands (See arrow, Figure 2) elicting a desmoplastic
stromal response (Figure 2, asterisk). The glands were
lined by cells with abundant eosinophilic cytoplasm with
pleomorphic nuclei, diagnostic of pancreatic adenocarci-
noma. While the predominant part of the tumor was
moderately differentiated, foci of single atypical cells
infiltrating the pancreatic parenchyma (Figure 2), consis-
tent with a poorly differentiated component were also
noted. (Figure 3, arrow). The tumor exhibited invasion
into peripancreatic fat and metastasis was indentified in
2 out of 25 resected lymph nodes. Pancreatic
Intraepithelial Neoplasia 1A and 1B were also present.
Following recovery from surgery, she underwent radia-
tion therapy and chemotherapy with Gemcitabine and
5-FU. She remained clinically well until age 38 when
she developed rapid progression of liver disease with
ascites, spider telangiectasias, worsening jaundice and
evidence of portal hypertension. Further evaluation
demonstrated an intrahepatic mass thought to be a
HCC and multiple pulmonary nodules that were positive
for adenocarcinoma. A TIPS procedure was performed
for control of portal hypertension, but she developed
sepsis and died soon thereafter.
Figure 1 CT scan of abdomen with pancreatic mass (arrow).
Figure 2 Low magnification of pancreatic mass showing an
infiltrative tumor composed of angulated glands (see arrow)
distributed irregularly in a desmoplastic stroma (asterisk).
Figure 3 Higher magnification of the tumor shows tumor
glands lined by cells with abundant eosinophilic cytoplasm
with enlarged, hyperchromatic nuclei. While most of the tumor
was a grade 2 adenocarcinoma, foci of single atypical cells (see
arrow) infiltrating the pancreatic parenchyma, consistent with a
poorly differentiated component, was also present.
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Conclusions
Chronic cholestasis in children is often the result of
genetic disease. Mutations in ATP8B1 (encoding for
FIC1) and ABCB11 (encoding for BSEP) are the com-
mon causes of PFIC that are associated with relatively
low serum gamma-glutamyl transferase (GGT) activity,
so called low-GGT PFIC. They are very similar in pre-
sentation and both may respond to bile diversion ther-
apy. However, patients with BSEP disease appear to
have much greater risk for hepatobiliary cancer than do
those with FIC1 disease. This case suggests that pan-
creatic cancer should be added to the list of cancers
these patients are at potential risk for developing. We
can only speculate on why this BSEP disease patient
developed early onset pancreatic adenocarcinoma.
Pancreatic cancer is the third most common gastroin-
testinal malignancy in the United States. In 2007, more
than 37,000 new cases were diagnosed in the US. The
prognosis is poor: the 1 year survival is 26% and the 5
year survival rate 5%. Pancreatic cancer is the fourth
leading cause of cancer related death in the US. Even in
patients diagnosed with local disease, the 5 year survival
rate is 20% [6]. The woman reported herein is unusual
among pancreatic cancer cases for several reasons. First,
this condition is relatively rare in younger persons. Only
about 10% of cases are diagnosed before age 50 [7]. Sec-
ondly, it is somewhat more prevalent in males. Despite
the odds against it, this case may represent only coinci-
dence of two very rare conditions in one unfortunate
woman.
Familial risk factors unrelated to BSEP disease may
have placed her at increased risk. The patient had a sib-
ling with BSEP disease as well as several family mem-
bers apparently without BSEP disease who developed
cancer. This family history may imply a genetic risk fac-
tor for malignancy above and beyond BSEP disease
although the family members may be heterozygotes for
the BSEP mutation. Risk factors in early onset pancrea-
tic cancer include family history and cigarette smoking
[8], which this patient did not do. Genetic mutations in
pancreatic cancer have included loss of function of
tumor suppressor genes CDKN2A/p16, p53 and LKB1/
STK11 [9,10]. Mutant KRAS2, aberrant DNA methyla-
tion, and inactivation of TP53 and SMAD4 have been
implicated [11]. BRCA2 gene mutations are also com-
mon [12].
Exposure to bile acids may offer another explanation
for development of pancreatic adenocarcinoma in this
patient. Xiao and colleagues have found that epithelial
cells in liver cirrhosis exhibit features of hepatic stem
cells [13]. Damage induced by intrahepatic bile acids
can induce disorderly proliferation of stem cell elements
that can differentiate along biliary epithelial lines [14],
perhaps predisposing to intrahepatic cholangiocarci-
noma. Scheimann and colleagues report 2 cases of cho-
langiocarcinoma in the setting of BSEP deficiency, both
in the setting of intrahepatic cholestasis, fibrosis and
inflammation [3]. It is conceivable that the exposure of
pancreas cells to bile acids in our patients might also
predispose to damage leading to increased carcinogen-
esis. It is of interest that the development of pancreatic
cancer followed a period of protracted cholestasis
related to pregnancy whereas she had been free of cho-
lestasis for over a decade before. In opposition to this
theoretical mechanism, Lu and colleagues have demon-
strated that the growth of some pancreatic cancer cell
lines is inhibited by bile acids [15]. Furthermore, there is
no significant difference in the degree of cholestasis (i.e.
degree of serum bile salt elevation) in FIC1 disease and
other childhood cholestatic diseases such as Alagille syn-
drome as compared to BSEP disease. Finally, HCC has
developed in BSEP patients after complete resolution of
cholestasis and normalization of serum bile salt levels
with bile diversion therapy [2]. Thus, the toxicity of bile
salts in tissues and organs remote to hepatocytes as a
cause for increased cancer risk in BSEP disease seems
unlikely.
The hypothesis most likely explaining the develop-
ment of pancreatic adenocarcinoma in our patient
involves BSEP itself. BSEP may act as a tumor suppres-
sor gene, and its malfunction may predispose to onco-
genesis. Knisely and colleagues were the first to describe
the apparent high incidence of HCC in children with
BSEP deficiency. Eight of the 10 children had elevated
serum concentrations of AFP, and AFP was demon-
strated in the cytoplasm in all tumors. Nuclei in 8 of
the tumors stained for p53. b catenin accumulation was
not detected in any of the livers [2]. Strautnieks and col-
leagues identified 82 different ABCB11 mutations in 109
families with severe BSEP deficiency. Of affected
patients, 15% had HCC or cholangiocarcinoma. The
relative risk for cancer of two particular protein truncat-
ing mutations was significant, but the risk for malig-
nancy was still 10% in patients without protein
truncating defects [1]. Thus, at least in regard to HCC
and cholangiocarcinoma, the ABCB11 gene defect
appears to be an independent risk factor.
FIC1 is expressed in many tissues, most intensely in
bowel and liver, and FIC1 disease patients have disease
outside the liver including diarrhea, loss of hearing, and
pancreatic insufficiency [16]. In contrast BSEP is expressed
primarily in the liver. Thus, BSEP disease has few if any
primary extrahepatic manifestations, and exocrine pan-
creatic function is thought to be normal [17]. Despite the
fact that hepatocytes are the only cells in the body that
have BSEP expression [18], there is embryologic evidence
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for homology in pancreas and liver cells. The endoderm of
the ventral lateral foregut is induced into forming pancreas
and liver by interaction with the cardiogenic mesoderm
and expression of the homeobox gene Hex. Mice deficient
in Hex have failure of ventral pancreas expression [19].
The pancreas emerges independently from dorsal and ven-
tral domains of embryonic gut endoderm. The liver and
ventral pancreas are specified at the same time and in the
same general domain of cells. In embryo tissue explanta-
tion experiments in mice using ventral foregut endoderm,
it was found that the default fate of the ventral foregut
endoderm is to activate the pancreatic gene program.
However, if exposed to Fibroblast Growth Factor signaling
from the cardiac mesoderm, the ventral foregut endoderm
expresses genes for the liver [20]. Additionally, the gene
Hes 1 is a potential controller for the differentiation of
pancreas and biliary epithelium. Hes1 knock out mice
have agenesis of the gallbladder, hypoplastic extrahepatic
bile ducts and biliary epithelium that differentiates into
endocrine and exocrine like pancreatic structures [21].
Thus, the cells of the ventral foregut endoderm are pluri-
potential cells for the development of both pancreas and
liver. While it is unclear at which point in organ develop-
ment BSEP expression starts, it can be inferred based on
the origin of the cells that mutated BSEP may have an
impact on the pancreas. Thus the expression pattern of
BSEP is not supportive of this hypothesis, but it remains
possible that mutated BSEP may predispose to the devel-
opment of pancreatic adenocarcinoma.
In summary, this is the first case report describing
pancreatic adenocarcinoma in a patient with BSEP defi-
ciency. Recommendations already exist in this disorder
for screening of patients for HCC [2]. It stands to rea-
son that liver transplant would not replace defective
BSEP in the other cells of the body, despite normal liver
function. Thus, patients may remain at risk for this pan-
creatic cancer despite successful liver transplantation. As
the known population with this disorder ages, clinicians
should be aware of the possibility of pancreatic adeno-
carcinoma in patients with BSEP deficiency.
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